Read Time:11 Second
The stock of biotech Actinium Pharmaceutics Inc. tumbled 65% early Monday, after the Food and Drug Administration said a late-stage trial of its Iomab-B leukemia treatment is not enough to support a request for approval.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
